ArticleAntimicrobial agents and chemotherapy2023
Developing synergistic drug combinations to restore antibiotic sensitivity in drug-resistant
Article in Antimicrobial agents and chemotherapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 26 citations in OpenAlex.
- Genetic interference of distinctive Mycobacterium tuberculosis peptidoglycan modifications enhances β-lactam susceptibility and reveals expression-sensitive host immune dynamics.Scientific reports · 2026Article
- Strain diversity drives heterogeneous responses to tuberculosis combination therapy.Antimicrobial agents and chemotherapy · 2026Article
- Transcription attenuation amplifies collateral vulnerabilities in rifampicin-resistant Mycobacterium tuberculosis.Nature microbiology · 2026Article
- Menaquinone depletion resensitises bedaquiline-resistant tuberculosis.bioRxiv : the preprint server for biology · 2026Article
- Strain diversity drives heterogeneous responses to tuberculosis combination therapy.bioRxiv : the preprint server for biology · 2025Article
- Netupitant Exhibits Potent Activity onACS infectious diseases · 2025Article
- Antimicrobial efficiency of bromhexine hydrochloride against endometritis-causing Escherichia coli and Trueperella pyogenes in bovines.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- Targeting Intracellular Bacteria with Dual Drug-loaded Lactoferrin Nanoparticles.ACS infectious diseases · 2024Article
- Ethambutol and meropenem/clavulanate synergy promotes enhanced extracellular and intracellular killing ofAntimicrobial agents and chemotherapy · 2024Article
- Unlocking Opportunities forACS infectious diseases · 2024Review
- Fixed-Dose Combination Formulations in Solid Oral Drug Therapy: Advantages, Limitations, and Design Features.Pharmaceutics · 2024Review
- Insights into the in-vitro Susceptibility and Drug-Drug Interaction Profiles Against Drug-Resistant and SusceptibleInfection and drug resistance · 2024Article
- In vitro model to simulate multiple drugs with distinct elimination half-lives.International journal of antimicrobial agents · 2023Article
- The human proton pump inhibitors inhibitProceedings of the National Academy of Sciences of the United States of America · 2023Article
- Evolution of Antibacterial Drug Screening Methods: Current Prospects for Mycobacteria.Microorganisms · 2021Review
- Intracellular Accumulation of Novel and Clinically Used TB Drugs Potentiates Intracellular Synergy.Microbiology spectrum · 2021Article
- Antimycobacterial Activity, Synergism, and Mechanism of Action Evaluation of Novel Polycyclic Amines againstAdvances in pharmacological and pharmaceutical sciences · 2021Article
- Towards the sustainable discovery and development of new antibiotics.Nature reviews. Chemistry · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB) is a leading global cause of mortality owing to an infectious agent, accounting for almost one-third of antimicrobial resistance (AMR) deaths annually. We aimed to identify synergistic anti-TB drug combinations with the capacity to restore therapeutic efficacy against drug-resistant mutants of the causative agent,
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.